Characteristics of Long COVID-19 Syndrome

Sponsor
Christian Clarenbach (Other)
Overall Status
Recruiting
CT.gov ID
NCT04793269
Collaborator
(none)
200
1
38.2
5.2

Study Details

Study Description

Brief Summary

Characterization of patients with long COVID syndrome including symptoms, medical history and persistent organ damage.

Condition or Disease Intervention/Treatment Phase
  • Other: No intervention

Detailed Description

Some people are very hesitant to recover from a COVID-19 infection and present persistent symptoms. The participants still suffer after the acute phase of the infection from shortness of breath, coughing, chest pain or fatigue. Therefore, a special interdisciplinary consultation was built. The consulatation is not only addressed to people who have been hospitalized due to COVID-19, but also to those with mild symptoms during infection. During the consultation hours, personal health data are collected that serves as the basis for this research project.

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Long COVID Syndrom: Charakterisierung Eines Neuen Krankheitsbildes
Actual Study Start Date :
Feb 23, 2021
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Apr 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Long COVID

Patients with long COVID syndrome

Other: No intervention
no intervention

Outcome Measures

Primary Outcome Measures

  1. Dyspnea [once through study completion, an average of 6 months.]

    modified medical research council (scale from 0 to 4). The higher the score the worse the symptoms.

  2. self-addressed Quality of life [once through study completion, an average of 6 months]

    Short form health 36 questionnaire with 8 domains, each rated from 0-100. The higher the score the better subjective quality of life.

  3. Thoracic pain [once through study completion, an average of 6 months]

    assessed by medical interview (reported as yes or no)

  4. Medical history [once through study completion, an average of 6 months]

    List of relevant morbidities assessed as present/not present by medical interview (e.g. respiratory, cardial, neurological, psychiatric diseases by interview and medical records)

  5. Fibrosis [once through study completion, an average of 6 months]

    Assessed by chest CT, rated as present/not present

  6. Myocardial damage [once through study completion, an average of 6 months]

    Assessed by myocardial damage, rated as present/not present

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Long COVID syndrome

  • age >= 18 years

  • Informed consent

Exclusion Criteria:
  • none

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospital Zurich Zurich Switzerland 8091

Sponsors and Collaborators

  • Christian Clarenbach

Investigators

  • Study Chair: Christian F Clarenbach, MD, University Hospital Zurich, Pulmonology

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Christian Clarenbach, Sponsor Investigator, University of Zurich
ClinicalTrials.gov Identifier:
NCT04793269
Other Study ID Numbers:
  • 2021-00280
First Posted:
Mar 11, 2021
Last Update Posted:
Oct 7, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Christian Clarenbach, Sponsor Investigator, University of Zurich
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 7, 2021